Kidney failure stabilizes after an increase over 2 decades

Journal of Renal Care

Volumn 33, Issue 3, 2007, Pages 100-104

  Cravedi, Paolo ^a   Ruggenenti, Piero ^a   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

ACE inhibitor; Angiotensin receptor antagonist; Kidney failure; Proteinuria

Indexed keywords

EID: 34548209650     PISSN: 1019083X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2007.tb00052.x     Document Type: Article

References (21)

1. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Eng J Med 1998;339(20):1448-1456.
2. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116(2):288-296.
3. Rudnicki M, Eder S, Perco P, Enrich J, Scheiber K, Koppelstatter C, Schratzberger G, Mayer B, Oberbauer R, Meyer TW, Mayer G. Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. Kidney Int 2007; 71(4):325-335.
4. The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349(9069):1857-1863.
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001; 345(12): 861-869.
6. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77(6):1993-2000.
7. Mogensen CE. Long-term antihypertensive treatment inhibiting progression. BMJ (Clin Res Ed) 1983; 285(6343): 685-688.
8. Macconi D, Ghilardi M, Bonassi ME, Mohamed El, Abbate M, Colombi F, Remuzzi G, Remuzzi A. Effect of angiotensin-converting-enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in mwf rats. J Am Soc Nephrol. 2000; 11(3): 477-489.
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study Group. N Eng J Med 1993; 329(20):1456-1462.
10. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304(6823):339-343.
11. Breyer JA, Bain RP, Evans JK, Nahman NS JR, Lewis EJ, Cooper M, McGill J, Berl T. Predictors of the progression of renal insufficiency in patients with insulindependent diabetes and overtdiabetic nephropathy. The collaborative study group. Kidney Int. 1996; 50 (5): 1651-1658.
12. Nakamura T, Takahashi T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H. Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol. 1995; 5(7):1492-1497.
13. Remuzzi A, Gagliardini E, Sangalli F, Bonomelli M, Piccinelli M, Benigni A, Remuzzi G. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 2006; 69(7):1124-1130.
14. Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q, Salvadori M, Remuzzi G. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol. 1999; 10(5):997-1006.
15. Wilmer WA, Hebert LA, Lewis EJ, Rohde RD, Whittier F, Cattran D, Levey AS, Lewis JB, Spitalewitz S, Blumenthal S, Bain RP. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999; 34(2):308-314.
16. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): US kidney failure stabilizes, ending a 20-year climb. Troubling racial disparities persist. Available at: http://www.niddk.nih.gov/. Accessed January 25, 2007.
17. Ruggenenti P, Remuzzi G. Kidney failure stabilizes after two-decade increase: impact on global (renal and cardiovascular) health. Clin J Am Soc Nephrol 2007; 2:146.
18. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C, Abbate M, Remuzzi G. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002; 13(12):2898-2908.
19. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361(9352):117-124.
20. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int 1999; 71:S2-S5.
21. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357(9268):1601-1608.